USA - 18 Mar `18Aclaris Therapeutics: ATI-50002

Official Title: A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

In Brief: The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.

Detailed Description: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.

Ages Eligible: 18 Years to 65 Years 

Start Date: March 19, 2018

Completion Date (estimated): September 30, 2019

Status: Active, not recruiting

Study ID from NCT03468855
Other Study ID Numbers: ATI-50002-VITI-201

Locations: USA

  • Encinitas, California
  • Los Angeles, California
  • Worcester, Massachusetts
  • Dallas, Texas
  • Lynchburg, Virginia

Contact: To learn more about this study, you or your doctor may contact Aclaris Therapeutics.

FAQOther Questions

  • How can I explain vitiligo to my children?

    Vitiligo can be puzzling for a child because a person who has it isn't "ill" in a common sense.  To choose the right words to explain vitiligo diagnosis to a child, first consi...

  • What's better: laser or phototherapy?

    In a recent study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA and PUVA. No significa...

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...